Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,858 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.
Nickenig C, Dreyling M, Hoster E, Ludwig WD, Dörken B, Freund M, Huber C, Ganser A, Trümper L, Forstpointner R, Unterhalt M, Hiddemann W. Nickenig C, et al. Among authors: huber c. Ann Oncol. 2007 Jan;18(1):136-142. doi: 10.1093/annonc/mdl348. Epub 2006 Oct 27. Ann Oncol. 2007. PMID: 17071931 Free article. Clinical Trial.
Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia--initial results.
Ganser A, Heil G, Kolbe K, Maschmeyer G, Fischer JT, Bergmann L, Mitrou PS, Heit W, Heimpel H, Huber C, et al. Ganser A, et al. Among authors: huber c. Ann Hematol. 1993 Mar;66(3):123-5. doi: 10.1007/BF01697620. Ann Hematol. 1993. PMID: 7682447 Clinical Trial.
Outcome of peripheral blood stem cell mobilization in advanced phases of CML is dependent on the type of chemotherapy applied.
Fischer T, Neubauer A, Mohm J, Huhn D, Busemann C, Link H, Arseniev L, Büssing B, Novotny J, Ganser A, Duyster J, Bunjes D, Westermeier T, Flohr T, Desprès D, Gamm H, Decker J, Derigs G, Aulitzky W, Huber C. Fischer T, et al. Among authors: huber c. Ann Hematol. 1998 Jul-Aug;77(1-2):21-6. doi: 10.1007/s002770050406. Ann Hematol. 1998. PMID: 9760148 Clinical Trial.
Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia.
Hofmann WK, Seipelt G, Langenhan S, Reutzel R, Schott D, Schoeffski O, Illiger HJ, Hartmann F, Balleisen L, Franke A, Fiedler F, Huber C, Rasche H, Bergmann L, Ganser A, Pott C, Pasold R, Rudolph C, Ottmann OG, Gökbuget N, Hoelzer D. Hofmann WK, et al. Among authors: huber c. Ann Hematol. 2002 Oct;81(10):570-4. doi: 10.1007/s00277-002-0542-8. Epub 2002 Oct 17. Ann Hematol. 2002. PMID: 12424538 Clinical Trial.
Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CML.
Fischer T, Neubauer A, Mohm J, Huhn D, Busemann C, Link H, Arseniev L, Büssing B, Novotny J, Ganser A, Duyster J, Bunjes D, Kreiter S, Aulitzky W, Hehlmann R, Huber C. Fischer T, et al. Among authors: huber c. Bone Marrow Transplant. 1998 May;21(10):1029-36. doi: 10.1038/sj.bmt.1701229. Bone Marrow Transplant. 1998. PMID: 9632277
High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. German GABG-4/EH-93-Study.
Zander AR, Krüger W, Kröger N, Damon L, Königmann M, Berdel WE, Gieseking F, Schäfer-Eckart K, Möbus V, Frickhofen N, Wandt H, Illiger HJ, Metzner B, Kolbe K, Wörmann B, Trümper L, Huber C, Hossfeld DK, Maass H, Jonat W. Zander AR, et al. Among authors: huber c. Bone Marrow Transplant. 1996 Sep;18 Suppl 1:S24-5. Bone Marrow Transplant. 1996. PMID: 8899165 Clinical Trial. No abstract available.
Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study.
Schuler M, Herrmann R, De Greve JL, Stewart AK, Gatzemeier U, Stewart DJ, Laufman L, Gralla R, Kuball J, Buhl R, Heussel CP, Kommoss F, Perruchoud AP, Shepherd FA, Fritz MA, Horowitz JA, Huber C, Rochlitz C. Schuler M, et al. Among authors: huber c. J Clin Oncol. 2001 Mar 15;19(6):1750-8. doi: 10.1200/JCO.2001.19.6.1750. J Clin Oncol. 2001. PMID: 11251006 Clinical Trial.
Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.
Hess G, Flohr T, Huber C, Kolbe K, Derigs HG, Fischer T. Hess G, et al. Among authors: huber c. Bone Marrow Transplant. 2003 May;31(9):775-82. doi: 10.1038/sj.bmt.1703925. Bone Marrow Transplant. 2003. PMID: 12732884 Clinical Trial.
1,858 results